Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMYRIS, INC.AMRS · Entity 91367 | Director | August 05, 2020 | August 08, 2020 |
| CODEXIS, INC.CDXS · Entity 6428 | Director | June 14, 2022 | June 16, 2022 |
| Sana Biotechnology, Inc.SANA · Entity 4870 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMYRIS, INC.
Report date August 05, 2020 · Filed August 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,793 |
Reported balance
After 2020-08-05 transaction · row 1
1 source rowRow 1 · 2020-08-05 · Grant · Acquired 2,266 · Balance 45,793 F1: Represents a restricted stock unit award that vests as to 100% of the units on August 5, 2021. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.94 · Expires 2030-08-05 | Direct | 3,466 |
Reported balance
After 2020-08-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-08-05 · Grant · Acquired 3,466 · Balance 3,466 F2: Stock option vests as to 100% of the shares underlying the stock option on August 5, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award that vests as to 100% of the units on August 5, 2021.
F2: Stock option vests as to 100% of the shares underlying the stock option on August 5, 2021.
CODEXIS, INC.
Report date June 14, 2022 · Filed June 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,785 |
Reported balance
After 2022-06-14 transaction · row 1
1 source rowRow 1 · 2022-06-14 · Grant · Acquired 11,273 · Balance 53,785 F1: The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.
Sana Biotechnology, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-03 | Direct | 90,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 90,000 · Balance 90,000 F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ANDEAVOR LLC
Report date October 01, 2018 · Filed October 02, 2018
Section 16 reporting ended · disclosed 2018-10-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-10-01 transaction · row 1
1 source rowRow 1 · 2018-10-01 · Disposition to issuer · Disposed 6,682 · Balance 0 F1: Includes 1,145 restricted stock units. F2: Pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among the Issuer, Marathon Petroleum Corporation ("MPC"), Mahi Inc. and Mahi LLC (as amended, the "Merger Agreement"), at the effective time, each outstanding share of the Issuer's common stock was cancelled and became exchangeable for, at the holder's election, either $152.27 in cash or 1.87 shares of MPC common stock, subject to an allocation and proration whereby the outstanding shares of Issuer's common stock would be exchanged for approximately $3.5 billion in cash with the balance of shares exchanged for MPC shares, and each restricted stock unit was accelerated and cancelled in exchange for $152.27 in cash. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-10-01 · Disposition to issuer · Disposed 6,786 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time, each restricted stock unit for which the reporting person had previously elected to defer distribution was accelerated and cancelled in exchange for $152.27 in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,145 restricted stock units.
F2: Pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among the Issuer, Marathon Petroleum Corporation ("MPC"), Mahi Inc. and Mahi LLC (as amended, the "Merger Agreement"), at the effective time, each outstanding share of the Issuer's common stock was cancelled and became exchangeable for, at the holder's election, either $152.27 in cash or 1.87 shares of MPC common stock, subject to an allocation and proration whereby the outstanding shares of Issuer's common stock would be exchanged for approximately $3.5 billion in cash with the balance of shares exchanged for MPC shares, and each restricted stock unit was accelerated and cancelled in exchange for $152.27 in cash.
F3: Pursuant to the Merger Agreement, at the effective time, each restricted stock unit for which the reporting person had previously elected to defer distribution was accelerated and cancelled in exchange for $152.27 in cash.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2017 Filed May 22, 2017 23:36 UTC | AMYRIS, INC. AMRS · Entity 91367 | PurchaseCommon Stock | 100,000 | $0.29 | $29,050.00 |
DisclosureSEC source: 0001365916-17-000032 · edgar.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,000 F1 · shares: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.2855 to $0.2928 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1). Read SEC document |
| May 04, 2017 Filed May 5, 2017 19:18 UTC | ANDEAVOR LLC TSO · Entity 143162 | GrantCommon Stock | 2,028 | $0.00 | $0.00 |
DisclosureSEC source: 0000050104-17-000108 · wf-form4_149402632116066.xml · nonDerivative · entry 2 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,537 F2 · security: Annual non-employee director restricted stock unit award granted under the Amended and Restated Tesoro Corporation 2011 Long-Term Incentive Plan. The restricted stock units, along with their accrued dividend equivalent rights, will vest on the first anniversary of the grant date. Read SEC document |
| May 03, 2017 Filed May 5, 2017 19:18 UTC | ANDEAVOR LLC TSO · Entity 143162 | Exercise / conversionRestricted Stock Units · Derivative | 2,035 | $0.00 | $0.00 |
DisclosureSEC source: 0000050104-17-000108 · wf-form4_149402632116066.xml · derivative · entry 3 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,786 Underlying: Common Stock · 2,035 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Vesting and settlement of restricted stock units previously granted under the Amended and Restated Tesoro Corporation 2011 Long-Term Incentive Plan. F3 · derivative.exercise_date: The restricted stock units were granted on May 3, 2016 and vested on the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units were granted on May 3, 2016 and vested on the first anniversary of the grant date. Read SEC document |
| May 03, 2017 Filed May 5, 2017 19:18 UTC | ANDEAVOR LLC TSO · Entity 143162 | Exercise / conversionCommon Stock | 2,035 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000050104-17-000108 · wf-form4_149402632116066.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Vesting and settlement of restricted stock units previously granted under the Amended and Restated Tesoro Corporation 2011 Long-Term Incentive Plan. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 00:24 UTC | CODEXIS, INC. CDXS · Entity 6428 | PurchaseCommon Stock | 10,000 | $4.83 | $48,300.00 |
DisclosureSEC source: 0001140361-16-086863 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,340 F1 · price: This transaction was executed in multiple trades in prices ranging from $4.775 to $4.85, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| August 21, 2015 Filed Dec 8, 2017 02:22 UTC | CODEXIS, INC. CDXS · Entity 6428 | PurchaseCommon Stock | 10,000 | $3.98 | $39,769.00 |
DisclosureSEC source: 0001140361-17-045397 · doc1.xml · nonDerivative · entry 1 Yang Patrick Y · CIK 0001309988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,234 F1 · price: This transaction was executed in multiple trades in prices ranging from $3.94 to $3.99, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.